王佳颖（邮箱：Wangjy@njucm.edu.cn）, 博士，副教授，硕士生研究生导师，药理学系副主任。江苏省“青蓝工程”优秀骨干教师培养对象。主要研究方向研究方向为神经退行性疾病药靶与药物研究。

主持国家自然科学基金2项，江苏省高校自然科学重大项目1项，江苏省“十四五”教育科学规划青年专项课题1项。相关研究成果发表SCI学术论文24篇，累计影响因子超200分，H指数15；获授权中国发明专利9项、美国发明专利1项。并有1项专利实施转让，转让收益300万元。参与翻译著作《阿尔兹海默症的系统生物学》1部，参编十四五高等教育规划教材2部。目前担任MedComm, Neural Regeneration Research, Journal of Translational Medicine, Antioxidants等学术杂志审稿专家。

代表性论文

(1) Jianlu lv#, Danyang Zhu#, Ze Wang#, Jianqiao Fang, Yuanji Zhao, Lin Ma, Yun Tang*, Jiaying Wang*, Xu Shen*. Vincamine as a GPR40 agonist shows potential in treating female Alzheimer's disease. Phytomedicine. 2026, 152:157855.

(2) Jiawen Xu#, Lin Ma#, Yu Xiang, Mengqing Dai, Qiuhui Li, Xiaoyan Jin, Yuan Ruan, Yang Li*, Jiaying Wang*, Xu Shen*, Glabridin as a selective Kv2.1 inhibitor ameliorates DPN pathology by disrupting the Aβ/Kv2.1/JNK/NF-κB/NLRP3/p-Tau pathway. Acta Pharmacol Sin. 2025, 46(8):2163-2179.

(3) Jian Lu#, Qian Zhou#, Danyang Zhu#, Hongkuan Song, Guojia Xie, Xuejian Zhao, Yujie Huang, Peng Cao*, Jiaying Wang*, Xu Shen*, Drofenine as a Kv2.1 inhibitor alleviated AD-like pathology in mice through Aβ/Kv2.1/microglial NLRP3/neuronal Tau axis, Acta Pharm Sin B, 2025, 15(2025):371-391.

(4) Jian Lu#, Anxu He#, Zhuoying Jin#, Meng Zhang, Zhongxin Li, Fan Zhou, Lin Ma, Hongming Jin, Jiaying Wang*, Xu Shen*, Desloratadine alleviates ALS-like pathology in hSOD1G93A mice via targeting 5HTR2A on activated spinal astrocytes. Acta Pharmacol Sin, 2024，45(5):926-944.

(5) Xialin Zhu#, Yun Chen#, Xu Xu#, Xiaoju Xu, Yin Lu, Xi Huang, Jinpei Zhou, Lihong Hu, Jiaying Wang*, Xu Shen*, SP6616 as a Kv2.1 inhibitor efficiently ameliorates peripheral neuropathy in diabetic mice. EBioMedicine, 2020, 61, 103061. (封面文章)